CDEK
← All drugs Report issue

triapine

Small moleculeexperimental

Triapine is an investigational drug that is being evaluated for the treatment of cancer. It is a thiosemicarbazone derivative of 3-aminopyridine-2-carboxaldehyde. It presents an N-N-S array of donor sites that strongly bind iron, robbing iron-containing enzymes of their prosthetic group. — Wikipedia

Clinical trial activity

34 trials · 19 clinical orgs · 0 marketing orgs

Phase 1
18
Phase 2
16
Phase 3
0
Phase 4
0

Earliest trial started May 1, 1998 (NCT00004213)

Timeline

1990s

  1. Jan 1, 1998

    Earliest Phase 1 Sponsor(trial)

2000s

  1. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

NC(=S)N/N=C/c1ncccc1N
Mol. weight
195.25 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
  • 3-apct
  • nsc 663249
  • pan811
  • pan 811
  • pan-811
  • triapine
  • triapine
  • triapine
  • triapine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06860594Phase 1Apr 21, 2025City of Hope National Medical Center, National Cancer Institute (NCI)
NCT06410248Phase 1Jul 23, 2024National Cancer Institute (NCI), Northwestern University
NCT05724108Phase 2Aug 30, 2023National Cancer Institute (NCI), Ohio State University
NCT04494113Early Phase 1 (Phase 1)Nov 27, 2020Johns Hopkins University, National Cancer Institute (NCI)
NCT04234568Phase 1Nov 6, 2020National Cancer Institute (NCI), Ohio State University
NCT02595879Phase 1May 27, 2016National Cancer Institute (NCI), University of Pittsburgh
NCT02466971Phase 2Jan 15, 2016National Cancer Institute (NCI), NRG Oncology
NCT00941070Phase 2Jul 1, 2009Case Western Reserve University, National Cancer Institute (NCI)
NCT00288093Phase 1Dec 20, 2006National Cancer Institute (NCI), Ohio State University
NCT00390052Phase 1Dec 1, 2006City of Hope National Medical Center, National Cancer Institute (NCI)
NCT00381550Phase 2Aug 1, 2006Johns Hopkins University, National Cancer Institute (NCI)
NCT00293345Phase 1Jun 1, 2006National Cancer Institute (NCI), Ohio State University
NCT00335998Phase 1Mar 1, 2006Case Western Reserve University, National Cancer Institute (NCI)
NCT00081276Phase 2Jul 1, 2005Gynecologic Oncology Group, National Cancer Institute (NCI)
NCT00095888Phase 2Oct 1, 2004Mayo Clinic, National Cancer Institute (NCI)
NCT00077350Phase 2Jul 1, 2004Eastern Cooperative Oncology Group, National Cancer Institute (NCI)
NCT00085371Phase 2Jul 1, 2004Mayo Clinic, National Cancer Institute (NCI)
NCT00078975Phase 2Apr 1, 2004National Cancer Institute (NCI), University of Toronto
NCT00077415Phase 2Apr 1, 2004Cancer Therapeutics Research Group, City University of Hong Kong, National Cancer Institute (NCI)
NCT00084877Phase 1Mar 1, 2004National Cancer Institute (NCI), University of Wisconsin
Showing 20 of 34 trials
Page 1 / 2

Organizations

Research & Development (19)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government262122003
Vion PharmaceuticalsFor profit8821998
Ohio State UniversityAcademic/Hospital4022006
Johns Hopkins UniversityAcademic/Hospital3122004
Case Western Reserve UniversityAcademic/Hospital2022006
City of Hope National Medical CenterAcademic/Hospital2012006
Mayo ClinicAcademic/Hospital2012004
University of ChicagoAcademic/Hospital2022004
University of TorontoAcademic/Hospital2112004
University of WisconsinAcademic/Hospital2012004
Canadian Cancer Trials GroupAcademic/Hospital1112004
Cancer Therapeutics Research GroupAcademic/Hospital1112004
City University of Hong KongAcademic/Hospital1012004
Eastern Cooperative Oncology GroupAcademic/Hospital1012004
Gynecologic Oncology GroupAcademic/Hospital1012005
Northwestern UniversityAcademic/Hospital1112024
NRG OncologyAcademic/Hospital1012016
University of PittsburghAcademic/Hospital1012016
Yeshiva UniversityAcademic/Hospital1012003
19 organizations
Page 1 / 1